Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Kent Y., Loungani, Rahul S., Rao, Vishal N., Patel, Chetan B., Khouri, Michel G., Felker, G. Michael, DeVore, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Primers in Cardio-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352120/
https://www.ncbi.nlm.nih.gov/pubmed/34396189
http://dx.doi.org/10.1016/j.jaccao.2019.11.006
_version_ 1783736114245271552
author Feng, Kent Y.
Loungani, Rahul S.
Rao, Vishal N.
Patel, Chetan B.
Khouri, Michel G.
Felker, G. Michael
DeVore, Adam D.
author_facet Feng, Kent Y.
Loungani, Rahul S.
Rao, Vishal N.
Patel, Chetan B.
Khouri, Michel G.
Felker, G. Michael
DeVore, Adam D.
author_sort Feng, Kent Y.
collection PubMed
description Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
format Online
Article
Text
id pubmed-8352120
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83521202021-08-13 Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy Feng, Kent Y. Loungani, Rahul S. Rao, Vishal N. Patel, Chetan B. Khouri, Michel G. Felker, G. Michael DeVore, Adam D. JACC CardioOncol Primers in Cardio-Oncology Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease. Elsevier 2019-12-17 /pmc/articles/PMC8352120/ /pubmed/34396189 http://dx.doi.org/10.1016/j.jaccao.2019.11.006 Text en © 2019 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Primers in Cardio-Oncology
Feng, Kent Y.
Loungani, Rahul S.
Rao, Vishal N.
Patel, Chetan B.
Khouri, Michel G.
Felker, G. Michael
DeVore, Adam D.
Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
title Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
title_full Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
title_fullStr Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
title_full_unstemmed Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
title_short Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
title_sort best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy
topic Primers in Cardio-Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352120/
https://www.ncbi.nlm.nih.gov/pubmed/34396189
http://dx.doi.org/10.1016/j.jaccao.2019.11.006
work_keys_str_mv AT fengkenty bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy
AT lounganirahuls bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy
AT raovishaln bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy
AT patelchetanb bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy
AT khourimichelg bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy
AT felkergmichael bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy
AT devoreadamd bestpracticesforprognosticevaluationofapatientwithtransthyretinamyloidcardiomyopathy

Ejemplares similares